SCHEDULE: Armistice Capital Discloses 8.95% Stake in Rigel Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares, representing 8.95% of Rigel Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating their beneficial ownership of 1,672,000 shares of Rigel Pharmaceuticals, Inc. common stock.
• This holding represents 8.95% of the total outstanding shares of Rigel Pharmaceuticals, Inc.
• The filing is an amendment (Amendment No. 1) and the event date requiring the filing is June 30, 2026.
• Armistice Capital, LLC acts as the investment manager for the Master Fund, which directly holds the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not controlling stake in Rigel Pharmaceuticals. The filing indicates a substantial investment by Armistice Capital, LLC, which could signal confidence in the company's future prospects, but it does not inherently suggest immediate positive or negative catalysts.

Positives

• Significant institutional ownership established by Armistice Capital, LLC, potentially indicating confidence in Rigel Pharmaceuticals' long-term value.
• The 8.95% stake is a substantial minority holding, suggesting a notable investor presence.

Negatives

• The filing does not provide specific reasons for the investment or any strategic intentions beyond standard reporting requirements.
• The Master Fund disclaims beneficial ownership due to the investment management agreement, which is a standard but notable detail in such filings.

Risks

• Potential for increased volatility in Rigel Pharmaceuticals' stock price due to the significant stake held by a single entity.
• Future actions by Armistice Capital, such as further accumulation or divestment, could impact the stock price.

Future Outlook

The filing itself does not contain forward-looking statements or specific guidance regarding Rigel Pharmaceuticals' future performance. It is a disclosure of ownership.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings are common in the biotechnology and pharmaceutical sectors, often indicating active or activist investors seeking to influence company strategy or capitalize on perceived undervaluation. Rigel Pharmaceuticals operates in a highly competitive and R&D-intensive industry.

Stakeholder Impact

• Shareholders: May see increased trading volume and potential price fluctuations due to the significant stake and potential future actions of Armistice Capital.
• Management and Board of Directors: May need to consider the influence of a significant institutional investor and potentially engage with Armistice Capital regarding company strategy.

Next Steps

• Armistice Capital, LLC and Steven Boyd will continue to hold their beneficial ownership of Rigel Pharmaceuticals, Inc. common stock.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership or other reportable events.

Key Dates

Recommendation

The filing indicates a significant investment by Armistice Capital, which could be a positive signal, but it does not provide enough information about the company's performance or Armistice Capital's specific intentions to warrant a buy or sell recommendation. A 'hold' position allows for further observation of Rigel Pharmaceuticals' operational progress and any potential strategic engagement from the new significant shareholder.

Keywords

Rigel Pharmaceuticals, Armistice Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management